Maze Therapeutics: Coloma trust sells 26,563 shares

The sales were effected under a Rule 10b5-1 trading plan adopted by Maze Therapeutics' chief executive on February 6, 2026.

Available on EDGAR 11/04/2026 - 04:14 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) Chief Executive Officer Jason V. Coloma reported sales by two trusts on November 2, 2026. The Coloma 2021 Irrevocable Trust sold 2,257 shares at a weighted average price of $30.1241 per share and 336 shares at a weighted average price of $30.9089 per share; Coloma Family Trust sold 26,563 shares at a weighted average price of $30.0950 per share and 5,345 shares at a weighted average price of $31.0528 per share. All four transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Coloma on February 6, 2026.

Insider Trade Summary 10b5-1

Net Seller: 34,501 shares

Net Sell 4 txns

Insider Coloma Jason V

Role Chief Executive Officer

Sold 34,501 shs ($1.04M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	2,257	$30.1241	$68K
Sale	Common Stock F1, F4, F3	336	$30.9089	$10K
Sale	Common Stock F1, F5, F6	26,563	$30.095	$799K
Sale	Common Stock F1, F7, F8, F6	5,345	$31.0528	$166K

Holdings After Transaction: Common Stock — 12,965 shares (Indirect, The Coloma 2021 Irrevocable Trust); Common Stock — 186,901 shares (Indirect, Coloma Family Trust)

Footnotes (8)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.805 to $30.795 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4, 5, and 7 of this Form 4.
3. F3. These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.805 to $31.70 per share, inclusive.
5. F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.78 to $30.7175 per share, inclusive.
6. F6. These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.
7. F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.795 to $31.70 per share, inclusive.
8. F8. Reflects the transfer of 27,362 shares of Common Stock by the reporting person to the Coloma Family Trust on November 3, 2026.

Key Figures

Shares sold — The Coloma 2021 Irrevocable Trust: 2,257 shares Weighted average sale price — The Coloma 2021 Irrevocable Trust: $30.1241 per share Shares sold — The Coloma 2021 Irrevocable Trust: 336 shares +5 more

8 metrics

Shares sold — The Coloma 2021 Irrevocable Trust 2,257 shares Transaction on November 2, 2026

Weighted average sale price — The Coloma 2021 Irrevocable Trust $30.1241 per share Transaction on November 2, 2026

Shares sold — The Coloma 2021 Irrevocable Trust 336 shares Transaction on November 2, 2026

Weighted average sale price — The Coloma 2021 Irrevocable Trust $30.9089 per share Transaction on November 2, 2026

Shares sold — Coloma Family Trust 26,563 shares Transaction on November 2, 2026

Weighted average sale price — Coloma Family Trust $30.0950 per share Transaction on November 2, 2026

Shares sold — Coloma Family Trust 5,345 shares Transaction on November 2, 2026

Weighted average sale price — Coloma Family Trust $31.0528 per share Transaction on November 2, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, co-trustees

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

co-trustees technical

"serve as co-trustees"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MAZE shares did Jason V. Coloma's trusts sell, and at what prices?

On November 2, 2026, The Coloma 2021 Irrevocable Trust sold 2,257 shares at a weighted average price of $30.1241 per share and 336 shares at $30.9089 per share. Coloma Family Trust sold 26,563 shares at $30.0950 per share and 5,345 shares at $31.0528 per share. The transactions were made under a Rule 10b5-1 trading plan adopted by Coloma on February 6, 2026.

What price ranges were reported for the MAZE trust sales?

The 2,257-share sale was within a range of $29.805 to $30.795 per share, inclusive; the 336-share sale was within $30.805 to $31.70 per share, inclusive. The 26,563-share sale was within $29.78 to $30.7175 per share, inclusive, and the 5,345-share sale was within $30.795 to $31.70 per share, inclusive.

Did Jason V. Coloma transfer shares to Coloma Family Trust?

A footnote reports a transfer of 27,362 shares of Common Stock by Jason V. Coloma to Coloma Family Trust on November 3, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coloma Jason V

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		S(1)		2,257	D	$30.1241(2)	13,301	I	The Coloma 2021 Irrevocable Trust(3)
Common Stock	11/02/2026		S(1)		336	D	$30.9089(4)	12,965	I	The Coloma 2021 Irrevocable Trust(3)
Common Stock	11/02/2026		S(1)		26,563	D	$30.095(5)	164,884	I	Coloma Family Trust(6)
Common Stock	11/02/2026		S(1)		5,345	D	$31.0528(7)	186,901(8)	I	Coloma Family Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.805 to $30.795 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4, 5, and 7 of this Form 4.

3. These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.805 to $31.70 per share, inclusive.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.78 to $30.7175 per share, inclusive.

6. These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.

7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.795 to $31.70 per share, inclusive.

8. Reflects the transfer of 27,362 shares of Common Stock by the reporting person to the Coloma Family Trust on November 3, 2026.

	/s/ Courtney Phillips, as attorney-in-fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)